Basic Sprycel Information

• INN (International Nonproprietary Name): Dasatinib.
• Brand Names Available In United Kingdom: Sprycel, manufactured and distributed by Bristol‑Myers Squibb, supplied in protective bottles with child‑resistant caps; common strengths include 20 mg, 50 mg, 70 mg (bottles of 60) and 80 mg, 100 mg, 140 mg (bottles of 30 or 60).
• ATC Code: L01EA02 (antineoplastic agents; protein kinase inhibitors; dasatinib).
• Forms & Dosages: Tablets only; typical strengths sold are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg with packaging as noted above; no injectable, solution or topical forms are marketed.
• Manufacturers In United Kingdom: Originator company is Bristol‑Myers Squibb with partnered distribution arms for Europe; local supply is through licensed wholesalers.
• Registration Status In United Kingdom: Approved in EU/EMA with indications for Ph+ CML and Ph+ ALL and paediatric extensions; included on the WHO List Of Essential Medicines since 2017.
• OTC / Rx Classification: Prescription Only (Rx) in major markets including the UK.

Latest Research Highlights (Uk & Eu Focus)

Clinicians frequently ask whether new data change how dasatinib is used in the UK and EU.

Recent clinical evidence from 2022–2025 reinforced dasatinib’s established role for Philadelphia‑positive (Ph+) chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia.

UK tertiary centre registries reported sustained deep molecular responses (MR4–MR4.5) in a substantial subset of patients at 24 months, mirroring outcomes seen in multicentre EU cohorts.

Observational datasets emphasise dasatinib as a second‑line option after imatinib failure or intolerance and support paediatric protocols dosed by body surface area.

Safety updates continued to flag pleural effusion and myelosuppression as important adverse events in routine practice.

Pooled safety analyses from 2022–2024 estimated pleural effusion incidence at approximately 10–15% over two years in older adults, prompting closer monitoring in that group.

Pharmacovigilance data from MHRA Yellow Card and EudraVigilance picked up QT prolongation and bleeding signals at low frequency but clinically relevant in patients with comorbidities and interacting medicines.

Emerging research has concentrated on dose optimisation, comparing once‑daily 100 mg schedules with lower‑dose regimens and pilot de‑escalation for patients with sustained deep molecular response.

Regulatory and formulary discussions in NHS centres are increasingly guided by these real‑world registries and dose‑modification studies.

Key cataloguing data: INN Dasatinib; ATC L01EA02; WHO Essential Medicines inclusion (2017).

Clinical Effectiveness In The Uk (Nhs Data & Patient Reports)

Patients often want to know how well Sprycel works in NHS practice compared with trial results.

NHS outcome datasets and cancer registries show high rates of cytogenetic and molecular response with dasatinib, particularly when imatinib has failed or caused intolerance.

Real‑world NHS clinic audits report many patients reaching MR3 within 6–12 months and MR4+ by 24 months with continued therapy.

Patient‑reported outcomes collected via Patient.info and local NHS surveys highlight clear improvements in disease control and quality of life for most patients on dasatinib.

Persistent adverse effects reported by patients include fatigue, diarrhoea and fluid retention, which can affect daily activities and adherence.

The balance between durable disease suppression and chronic side effects leads some NHS teams to consider dose reductions or temporary treatment interruptions with close molecular monitoring.

Paediatric registries report comparable effectiveness when children are dosed by body surface area (60 mg/m², max 100 mg), in line with current practice.

Clinicians use shared decision‑making with patients when considering long‑term suppression versus trial entry for treatment‑free remission.

Data Highlights: many patients reach MR3 at 6–12 months; MR4+ rates increase by 24 months under continued therapy.

PRO Themes Checklist: disease control benefits; fatigue; diarrhoea; fluid retention; impact on daily energy and travel for hospital blood tests.

Indications & Expanded Uses (Mhra And Nhs Practice)

Patients and prescribers ask which conditions Sprycel is licensed to treat in the UK.

MHRA‑recognised indications in the UK align with EMA content: dasatinib (Sprycel) is indicated for Ph+ CML (newly diagnosed and resistant/intolerant cases) and Ph+ ALL, including paediatric use.

Typical NHS dosing used in practice is 100 mg once daily for chronic‑phase CML and 140 mg once daily for accelerated/blast phase CML and Ph+ ALL in adults.

In children, dasatinib is used at 60 mg/m² once daily (maximum 100 mg) often combined with chemotherapy in Ph+ ALL protocols.

Specialist centres may use dasatinib off‑label in combination protocols for relapsed ALL or within clinical trials that add immunotherapy agents.

NHS multidisciplinary teams require documented rationale and governance for off‑label prescriptions, and access routes include individual funding requests or trial enrolment.

Clinicians should record the indication, prior therapies (for example imatinib failure), and monitoring plans in the patient record.

Where off‑label use is considered, clear consent and governance documentation are essential before supply is arranged.

Composition & Brand Landscape (Active Ingredients, Packaging)

Many patients want a simple rundown of what Sprycel tablets contain and how they are supplied.

The active ingredient is dasatinib (INN) and the originator product is Sprycel, manufactured by Bristol‑Myers Squibb.

Sprycel tablets are typically supplied in child‑resistant bottles rather than blister packs.

Common UK packaging strengths mirror global supplies: 20 mg, 50 mg and 70 mg are usually bottles of 60; 80 mg, 100 mg are bottles of 30 or 60; 140 mg commonly in bottles of 30.

The ATC classification is L01EA02, reflecting its role as a protein kinase inhibitor used in oncology.

Generics are scarce in major markets, and the branded Sprycel product predominates in UK supply chains with distribution via licensed wholesalers.

Packaging Table:

Comparison Bullets:

• Imatinib (Glivec/Gleevec) is the historic first‑line with a different safety and interaction profile.
• Nilotinib, bosutinib and ponatinib are alternative TKIs used according to mutation status and comorbidities.

Contraindications & Special Precautions (High‑Risk Groups)

Patients and carers should understand when Sprycel is not suitable or needs extra caution.

Absolute contraindication is known hypersensitivity to dasatinib or any tablet excipients.

Special precautions include baseline and ongoing monitoring for QT prolongation, severe hepatic impairment and uncontrolled hypertension.

Prior bleeding disorders or platelet abnormalities require careful assessment before and during therapy.

Elderly patients face higher risks of myelosuppression and pleural effusion and should be monitored closely.

Pregnancy and breastfeeding present teratogenic risk and specialist obstetric advice is required; dasatinib is generally avoided in pregnancy.

Patients on anticoagulants need individual risk‑benefit assessment because bleeding signals have been reported.

Lifestyle advice includes avoiding heavy alcohol use, which can worsen hepatic toxicity and fatigue, and individualised driving guidance if dizziness or visual disturbance occurs.

Baseline Investigations: ECG, liver function tests, full blood count.

Monitoring Schedule: regular FBC and LFTs during induction and maintenance, ECG where indicated and clinical review for respiratory symptoms.

Dosage Guidelines (Nhs‑Recommended Regimens And Adjustments)

One common question is what dose to start and when to reduce or interrupt therapy.

Standard NHS dosing for adults is 100 mg once daily for chronic‑phase CML and 140 mg once daily for accelerated/blast phase CML and Ph+ ALL.

Paediatric dosing is by body surface area at 60 mg/m² once daily with a maximum of 100 mg daily.

Dose adjustments are advised for myelosuppression, severe hepatic impairment or other toxicity, and may include temporary interruption, dose reduction or supportive measures.

Elderly patients should start on standard doses but require closer monitoring and may need reductions more often.

If a dose is missed, patients should take the next scheduled dose and must not double up on the same day.

In overdose there is no specific antidote and treatment is supportive and symptomatic.

Simple Dose Table:

• Starting Dose (Adult Chronic): 100 mg once daily.
• Starting Dose (Adult Accelerated/Ph+ ALL): 140 mg once daily.
• Paediatric Note: 60 mg/m² once daily, max 100 mg.

Common Adjustment Triggers: neutropenia, thrombocytopenia, raised hepatic enzymes, symptomatic pleural effusion.

Interactions Overview (Food, Drink, Medicines, Yellow Card Signals)

Patients need to know which medicines and foods can affect dasatinib.

Dasatinib is metabolised via pathways affected by CYP3A4, so potent CYP3A4 inhibitors and inducers can alter exposure.

Avoid or review concomitant use of azole antifungals, certain antiretrovirals and other strong CYP3A4 modifiers with the oncology team.

Grapefruit products should be avoided as they may increase drug levels unpredictably.

Food does not strictly dictate dosing, but consistent habits reduce GI upset and improve tolerability.

Alcohol may exacerbate fatigue and hepatic risk and should be limited while on therapy.

MHRA Yellow Card and EudraVigilance entries have flagged interactions that can lead to QT prolongation and bleeding, particularly when combined with other QT‑prolonging agents or anticoagulants.

High‑Risk Co‑Medications Bullet List:

• Potent CYP3A4 inhibitors (e.g. certain azoles).
• Potent CYP3A4 inducers (may reduce efficacy).
• Other QT‑prolonging drugs and anticoagulants.

Data Highlight: Yellow Card reports emphasise caution when combining dasatinib with interacting medicines in patients with cardiovascular or bleeding comorbidities.

Cultural Perceptions & Patient Habits (Uk Patient Insight)

Many patients wonder where to find trustworthy information and how others manage long‑term TKI therapy.

UK patients commonly seek reassurance via NHS patient portals, Patient.info threads and community forums, and value pharmacist counselling in high‑street chains or hospital pharmacies.

Face‑to‑face counselling remains important, but electronic prescriptions and online pharmacy services are increasingly used for repeat dispensing and home delivery.

Patients place high trust in NHS oncology teams and pharmacists for medication‑specific advice and prefer clear, practical guidance on side‑effect management.

Key counselling topics patients request include recognition of pleural effusion signs, infection precautions and when to seek urgent review.

Shared decision‑making in NHS multidisciplinary teams is standard, and psychosocial support is often provided by Macmillan and local cancer charities.

Patient Information Touchpoints: NHS.uk pages, local oncology helplines, patient forums, community pharmacists.

Common Patient Concerns With Counselling Phrases:

• “How will this affect my energy?” — discuss fatigue management and activity pacing.
• “What if I get breathless?” — advise immediate contact if breathlessness or cough develops.
• “Can I travel?” — plan ahead for monitoring and carry contact details for the oncology team.

Availability & Pricing Patterns (Boots, Lloyds, Nhs Differences)

Patients often ask where they can collect Sprycel and what it costs on the NHS.

Sprycel is prescription‑only and distributed through NHS hospitals and community pharmacies; major chains such as Boots and LloydsPharmacy dispense under NHS or private prescriptions.

Regional differences in prescription charging affect out‑of‑pocket costs: England retains a flat charge system or exemptions, while Scotland, Wales and Northern Ireland generally exempt patients from prescription fees.

Private purchase of Sprycel is rare due to cost and the need for specialist supervision; most access is via NHS prescribing, individual funding requests or compassionate access programmes.

Branded Sprycel predominance and bottle packaging mean community pharmacists must source stock through licensed wholesalers and hospital pharmacies for specialist scripts.

NHS Vs Private Access Table:

In our online pharmacy, sprycel is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Nhs Prescribing Preferences

Clinicians weigh options when selecting which tyrosine kinase inhibitor to use for Ph+ CML.

Imatinib (Glivec/Gleevec) has been the historical first‑line therapy, while nilotinib (Tasigna), bosutinib (Bosulif) and ponatinib (Iclusig) are used depending on mutation profile and tolerance.

Ponatinib is uniquely active against the T315I mutation, which informs choice when that mutation is present.

Dasatinib’s broader SRC family kinase inhibition is useful in certain resistance patterns and makes it a common second‑line choice after imatinib failure.

Choice between agents depends on efficacy for the individual mutation, cardiac and vascular risk, myelosuppression risk and drug interaction profiles.

Pros/Cons Checklist For Clinicians And Patients:

• Efficacy: strong molecular responses with dasatinib in many second‑line cases.
• Cardiac Risks: nilotinib carries notable cardiovascular concerns; dasatinib has QT/pleural effusion considerations.
• Myelosuppression: common across TKIs and requires monitoring.
• Interactions and Cost: review CYP interactions and local formulary/reimbursement status.

Faq

Q1: Can I stop Sprycel once molecular remission is achieved?

A: Decisions about treatment discontinuation are specialist‑led with strict monitoring, and some patients may be trial candidates for treatment‑free remission under protocol.

Q2: What common side effects should prompt urgent contact?

A: Shortness of breath (possible pleural effusion), fever or signs of infection, severe bleeding or syncope require same‑day advice via NHS 111 or the oncology team.

Q3: How is Sprycel supplied and stored?

A: Supplied in child‑resistant bottles in strengths 20–140 mg; store at room temperature (20–25°C) and keep in original packaging.

Q4: Can I take Sprycel with herbal remedies?

A: Discuss all supplements with the treating team as some may alter metabolism and interact with dasatinib.

Action Steps And Contacts:

• For urgent symptoms call NHS 111 or your oncology nurse.
• Report suspected side effects via the MHRA Yellow Card scheme.
• For prescription queries contact your hospital pharmacy or community pharmacist.

Guidelines For Proper Use (Uk Pharmacist Counselling & Nhs Portals)

Pharmacists should use a structured counselling approach when dispensing Sprycel.

Confirm the indication (Ph+ CML or Ph+ ALL) and the prescribed dosing (100 mg or 140 mg for adults or paediatric BSA dosing as specified).

Check baseline investigations are recorded, including ECG, LFTs and full blood count, and advise on the monitoring schedule.

Counsel patients on common adverse events such as myelosuppression, pleural effusion and diarrhoea and explain when to seek urgent care.

Review potential interactions, especially CYP3A4 modifiers and concurrent anticoagulants, and advise consistent food habits to reduce GI upset.

Reinforce missed dose guidance and storage at room temperature (20–25°C), and signpost NHS resources such as local oncology helplines, Macmillan and NHS.uk pages.

Advise Yellow Card reporting for suspected adverse reactions and document counselling in the patient record.

Pharmacist Counselling Checklist:

• Confirm indication and dose.
• Review baseline ECG/LFT/FBC and monitoring plan.
• Discuss side effects and interactions.
• Provide storage and missed‑dose instructions.

Monitoring Intervals Definition List:

• FBC: frequently during initiation, then per clinic protocol.
• LFTs: baseline and periodic checks.
• ECG: baseline in high‑risk patients and as clinically indicated.

Delivery Across United Kingdom